Apricus Biosciences to Present at the 9th Annual L

SAN DIEGO, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the 9th Annual LD Micro Main Event on Thursday, December 8, 2016, at 11:30 a.m. Pacific Time.  The conference will be held at the Luxe Sunset Hotel, in Los Angeles, California.  Mr. Pascoe will provide an update on the Company’s strategy and development plans surrounding Vitaros®.

A live audio webcast of the presentation can be accessed via the Investor Relations’ section of the Company's website at www.apricusbio.com . Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.

About Apricus Biosciences, Inc .

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros ^® , for the treatment of erectile dysfunction, is approved in Canada and certain countries in Europe, Latin America and the Middle East and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa ^™ , its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.

For further information on Apricus, visit http://www.apricusbio.com . 

*Vitaros ^® is a registered trademark of NexMed International Limited.  Such trademark is registered in certain countries throughout the world and pending registration in the United States.

CONTACT: Institutional / Retail Investors: Matthew Beck mbeck@troutgroup.com The Trout Group LLC (646) 378-2933